Expression of connective tissue growth factor in male breast cancer: Clinicopathologic correlations and prognostic value

Miangela M. Lacle, Paul J. Van Diest, Roel Goldschmeding, Elsken Van Der Wall, Tri Q. Nguyen

Research output: Contribution to journalArticle

Abstract

Connective tissue growth factor (CTGF/CCN2) is a member of the CCN family of secreted proteins that are believed to play an important role in the development of neoplasia. In particular, CTGF has been reported to play an important role in mammary tumorigenesis and to have prognostic value in female breast cancer (FBC). The aim of the present study was to investigate clinicopathologic correlations and prognostic value of CTGF in male breast cancer (MBC) and to compare these findings with FBC. For this, we studied CTGF protein expression by immunohistochemistry in 109 MBC cases and 75 FBC cases. In MBC, stromal CTGF expression was seen in the majority of the cases 78% (85/109) with high expression in 31/109 cases (28.4%), but expression in tumor cells was only seen in 9.2% (10/109) of cases. High stromal CTGF expression correlated with high grade and high proliferation index (>15%) assessed by MIB-1 immunohistochemical staining. CTGF expression in tumor epithelial cells did not correlate with any of the clinicopathologic features. In FBC, stromal CTGF expression positively correlated with mitotic count and tumor CTGF expression was associated with triple negative status of the tumor (p = 0.002). Neither stromal nor tumor epithelial cell CTGF expression had prognostic value in MBC and FBC. In conclusion, stromal CTGF expression was seen in a high percentage of MBC and was correlated with high grade and high proliferation index. In view of the important role of the microenvironment in cancer progression, this might suggest that stromal CTGF could be an interesting target for novel therapies and molecular imaging. However, the lack of association with prognosis warrants caution. The potential role of CTGF as a therapeutic target for triple negative FBC deserves to be further studied.

Original languageEnglish (US)
Article numbere0118957
JournalPLoS One
Volume10
Issue number3
DOIs
StatePublished - Mar 4 2015
Externally publishedYes

Fingerprint

Male Breast Neoplasms
Connective Tissue Growth Factor
connective tissues
breast neoplasms
growth factors
Tumors
Breast Neoplasms
Neoplasms
CCN Intercellular Signaling Proteins
Molecular imaging
Epithelial Cells
Triple Negative Breast Neoplasms
neoplasms
Molecular Imaging
Tumor Microenvironment
Proteins
Cells
epithelial cells
Carcinogenesis
Breast

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Lacle, M. M., Van Diest, P. J., Goldschmeding, R., Van Der Wall, E., & Nguyen, T. Q. (2015). Expression of connective tissue growth factor in male breast cancer: Clinicopathologic correlations and prognostic value. PLoS One, 10(3), [e0118957]. https://doi.org/10.1371/journal.pone.0118957

Expression of connective tissue growth factor in male breast cancer : Clinicopathologic correlations and prognostic value. / Lacle, Miangela M.; Van Diest, Paul J.; Goldschmeding, Roel; Van Der Wall, Elsken; Nguyen, Tri Q.

In: PLoS One, Vol. 10, No. 3, e0118957, 04.03.2015.

Research output: Contribution to journalArticle

Lacle, Miangela M. ; Van Diest, Paul J. ; Goldschmeding, Roel ; Van Der Wall, Elsken ; Nguyen, Tri Q. / Expression of connective tissue growth factor in male breast cancer : Clinicopathologic correlations and prognostic value. In: PLoS One. 2015 ; Vol. 10, No. 3.
@article{ad73a415499b4758860e4f0cd7a97f31,
title = "Expression of connective tissue growth factor in male breast cancer: Clinicopathologic correlations and prognostic value",
abstract = "Connective tissue growth factor (CTGF/CCN2) is a member of the CCN family of secreted proteins that are believed to play an important role in the development of neoplasia. In particular, CTGF has been reported to play an important role in mammary tumorigenesis and to have prognostic value in female breast cancer (FBC). The aim of the present study was to investigate clinicopathologic correlations and prognostic value of CTGF in male breast cancer (MBC) and to compare these findings with FBC. For this, we studied CTGF protein expression by immunohistochemistry in 109 MBC cases and 75 FBC cases. In MBC, stromal CTGF expression was seen in the majority of the cases 78{\%} (85/109) with high expression in 31/109 cases (28.4{\%}), but expression in tumor cells was only seen in 9.2{\%} (10/109) of cases. High stromal CTGF expression correlated with high grade and high proliferation index (>15{\%}) assessed by MIB-1 immunohistochemical staining. CTGF expression in tumor epithelial cells did not correlate with any of the clinicopathologic features. In FBC, stromal CTGF expression positively correlated with mitotic count and tumor CTGF expression was associated with triple negative status of the tumor (p = 0.002). Neither stromal nor tumor epithelial cell CTGF expression had prognostic value in MBC and FBC. In conclusion, stromal CTGF expression was seen in a high percentage of MBC and was correlated with high grade and high proliferation index. In view of the important role of the microenvironment in cancer progression, this might suggest that stromal CTGF could be an interesting target for novel therapies and molecular imaging. However, the lack of association with prognosis warrants caution. The potential role of CTGF as a therapeutic target for triple negative FBC deserves to be further studied.",
author = "Lacle, {Miangela M.} and {Van Diest}, {Paul J.} and Roel Goldschmeding and {Van Der Wall}, Elsken and Nguyen, {Tri Q.}",
year = "2015",
month = "3",
day = "4",
doi = "10.1371/journal.pone.0118957",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Expression of connective tissue growth factor in male breast cancer

T2 - Clinicopathologic correlations and prognostic value

AU - Lacle, Miangela M.

AU - Van Diest, Paul J.

AU - Goldschmeding, Roel

AU - Van Der Wall, Elsken

AU - Nguyen, Tri Q.

PY - 2015/3/4

Y1 - 2015/3/4

N2 - Connective tissue growth factor (CTGF/CCN2) is a member of the CCN family of secreted proteins that are believed to play an important role in the development of neoplasia. In particular, CTGF has been reported to play an important role in mammary tumorigenesis and to have prognostic value in female breast cancer (FBC). The aim of the present study was to investigate clinicopathologic correlations and prognostic value of CTGF in male breast cancer (MBC) and to compare these findings with FBC. For this, we studied CTGF protein expression by immunohistochemistry in 109 MBC cases and 75 FBC cases. In MBC, stromal CTGF expression was seen in the majority of the cases 78% (85/109) with high expression in 31/109 cases (28.4%), but expression in tumor cells was only seen in 9.2% (10/109) of cases. High stromal CTGF expression correlated with high grade and high proliferation index (>15%) assessed by MIB-1 immunohistochemical staining. CTGF expression in tumor epithelial cells did not correlate with any of the clinicopathologic features. In FBC, stromal CTGF expression positively correlated with mitotic count and tumor CTGF expression was associated with triple negative status of the tumor (p = 0.002). Neither stromal nor tumor epithelial cell CTGF expression had prognostic value in MBC and FBC. In conclusion, stromal CTGF expression was seen in a high percentage of MBC and was correlated with high grade and high proliferation index. In view of the important role of the microenvironment in cancer progression, this might suggest that stromal CTGF could be an interesting target for novel therapies and molecular imaging. However, the lack of association with prognosis warrants caution. The potential role of CTGF as a therapeutic target for triple negative FBC deserves to be further studied.

AB - Connective tissue growth factor (CTGF/CCN2) is a member of the CCN family of secreted proteins that are believed to play an important role in the development of neoplasia. In particular, CTGF has been reported to play an important role in mammary tumorigenesis and to have prognostic value in female breast cancer (FBC). The aim of the present study was to investigate clinicopathologic correlations and prognostic value of CTGF in male breast cancer (MBC) and to compare these findings with FBC. For this, we studied CTGF protein expression by immunohistochemistry in 109 MBC cases and 75 FBC cases. In MBC, stromal CTGF expression was seen in the majority of the cases 78% (85/109) with high expression in 31/109 cases (28.4%), but expression in tumor cells was only seen in 9.2% (10/109) of cases. High stromal CTGF expression correlated with high grade and high proliferation index (>15%) assessed by MIB-1 immunohistochemical staining. CTGF expression in tumor epithelial cells did not correlate with any of the clinicopathologic features. In FBC, stromal CTGF expression positively correlated with mitotic count and tumor CTGF expression was associated with triple negative status of the tumor (p = 0.002). Neither stromal nor tumor epithelial cell CTGF expression had prognostic value in MBC and FBC. In conclusion, stromal CTGF expression was seen in a high percentage of MBC and was correlated with high grade and high proliferation index. In view of the important role of the microenvironment in cancer progression, this might suggest that stromal CTGF could be an interesting target for novel therapies and molecular imaging. However, the lack of association with prognosis warrants caution. The potential role of CTGF as a therapeutic target for triple negative FBC deserves to be further studied.

UR - http://www.scopus.com/inward/record.url?scp=84929492487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929492487&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0118957

DO - 10.1371/journal.pone.0118957

M3 - Article

C2 - 25738829

AN - SCOPUS:84929492487

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e0118957

ER -